Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells

N. Kuzumaki, A. Suzuki, M. Narita, T. Hosoya, A. Nagasawa, S. Imai, K. Yamamizu, H. Morita, H. Nagase, Y. Okada, H. J. Okano, J. K. Yamashita, Hideyuki Okano, T. Suzuki, M. Narita

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: It is becoming increasingly recognised that opioids are responsible for tumour growth. However, the effects of opioids on tumour growth have been controversial.Methods:The effects of-opioid receptor (KOR) agonist on the growth of non-small cell lung cancer (NSCLC) cells were assessed by a cell proliferation assay. Western blotting was performed to ascertain the mechanism by which treatment with KOR agonist suppresses tumour growth. Results: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. These effects were abolished by co-treatment with the selective KOR antagonist nor-BNI. Furthermore, the growth-inhibitory effect of gefitinib in HCC827 cells was further enhanced by co-treatment with U50,488H. With regard to the inhibition of tumour growth, the addition of U50, 488H to H1975 cells produced a concentration-dependent decrease in phosphorylated- glycogen synthase kinase 3Β (p-GSK3Β).Conclusion:The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3Β.

Original languageEnglish
Pages (from-to)1148-1152
Number of pages5
JournalBritish Journal of Cancer
Volume106
Issue number6
DOIs
Publication statusPublished - 2012 Mar 13

Fingerprint

Opioid Receptors
Non-Small Cell Lung Carcinoma
Growth
Opioid Analgesics
Neoplasms
Glycogen Synthase Kinase 3
Western Blotting
Cell Proliferation
gefitinib

Keywords

  • κ-opioid receptor
  • gefitinib
  • non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kuzumaki, N., Suzuki, A., Narita, M., Hosoya, T., Nagasawa, A., Imai, S., ... Narita, M. (2012). Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. British Journal of Cancer, 106(6), 1148-1152. https://doi.org/10.1038/bjc.2011.574

Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. / Kuzumaki, N.; Suzuki, A.; Narita, M.; Hosoya, T.; Nagasawa, A.; Imai, S.; Yamamizu, K.; Morita, H.; Nagase, H.; Okada, Y.; Okano, H. J.; Yamashita, J. K.; Okano, Hideyuki; Suzuki, T.; Narita, M.

In: British Journal of Cancer, Vol. 106, No. 6, 13.03.2012, p. 1148-1152.

Research output: Contribution to journalArticle

Kuzumaki, N, Suzuki, A, Narita, M, Hosoya, T, Nagasawa, A, Imai, S, Yamamizu, K, Morita, H, Nagase, H, Okada, Y, Okano, HJ, Yamashita, JK, Okano, H, Suzuki, T & Narita, M 2012, 'Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells', British Journal of Cancer, vol. 106, no. 6, pp. 1148-1152. https://doi.org/10.1038/bjc.2011.574
Kuzumaki N, Suzuki A, Narita M, Hosoya T, Nagasawa A, Imai S et al. Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. British Journal of Cancer. 2012 Mar 13;106(6):1148-1152. https://doi.org/10.1038/bjc.2011.574
Kuzumaki, N. ; Suzuki, A. ; Narita, M. ; Hosoya, T. ; Nagasawa, A. ; Imai, S. ; Yamamizu, K. ; Morita, H. ; Nagase, H. ; Okada, Y. ; Okano, H. J. ; Yamashita, J. K. ; Okano, Hideyuki ; Suzuki, T. ; Narita, M. / Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells. In: British Journal of Cancer. 2012 ; Vol. 106, No. 6. pp. 1148-1152.
@article{3a1cddc4baff4b3f9343252c41d6508c,
title = "Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells",
abstract = "Background: It is becoming increasingly recognised that opioids are responsible for tumour growth. However, the effects of opioids on tumour growth have been controversial.Methods:The effects of-opioid receptor (KOR) agonist on the growth of non-small cell lung cancer (NSCLC) cells were assessed by a cell proliferation assay. Western blotting was performed to ascertain the mechanism by which treatment with KOR agonist suppresses tumour growth. Results: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. These effects were abolished by co-treatment with the selective KOR antagonist nor-BNI. Furthermore, the growth-inhibitory effect of gefitinib in HCC827 cells was further enhanced by co-treatment with U50,488H. With regard to the inhibition of tumour growth, the addition of U50, 488H to H1975 cells produced a concentration-dependent decrease in phosphorylated- glycogen synthase kinase 3Β (p-GSK3Β).Conclusion:The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3Β.",
keywords = "κ-opioid receptor, gefitinib, non-small cell lung cancer",
author = "N. Kuzumaki and A. Suzuki and M. Narita and T. Hosoya and A. Nagasawa and S. Imai and K. Yamamizu and H. Morita and H. Nagase and Y. Okada and Okano, {H. J.} and Yamashita, {J. K.} and Hideyuki Okano and T. Suzuki and M. Narita",
year = "2012",
month = "3",
day = "13",
doi = "10.1038/bjc.2011.574",
language = "English",
volume = "106",
pages = "1148--1152",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Effect of-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells

AU - Kuzumaki, N.

AU - Suzuki, A.

AU - Narita, M.

AU - Hosoya, T.

AU - Nagasawa, A.

AU - Imai, S.

AU - Yamamizu, K.

AU - Morita, H.

AU - Nagase, H.

AU - Okada, Y.

AU - Okano, H. J.

AU - Yamashita, J. K.

AU - Okano, Hideyuki

AU - Suzuki, T.

AU - Narita, M.

PY - 2012/3/13

Y1 - 2012/3/13

N2 - Background: It is becoming increasingly recognised that opioids are responsible for tumour growth. However, the effects of opioids on tumour growth have been controversial.Methods:The effects of-opioid receptor (KOR) agonist on the growth of non-small cell lung cancer (NSCLC) cells were assessed by a cell proliferation assay. Western blotting was performed to ascertain the mechanism by which treatment with KOR agonist suppresses tumour growth. Results: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. These effects were abolished by co-treatment with the selective KOR antagonist nor-BNI. Furthermore, the growth-inhibitory effect of gefitinib in HCC827 cells was further enhanced by co-treatment with U50,488H. With regard to the inhibition of tumour growth, the addition of U50, 488H to H1975 cells produced a concentration-dependent decrease in phosphorylated- glycogen synthase kinase 3Β (p-GSK3Β).Conclusion:The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3Β.

AB - Background: It is becoming increasingly recognised that opioids are responsible for tumour growth. However, the effects of opioids on tumour growth have been controversial.Methods:The effects of-opioid receptor (KOR) agonist on the growth of non-small cell lung cancer (NSCLC) cells were assessed by a cell proliferation assay. Western blotting was performed to ascertain the mechanism by which treatment with KOR agonist suppresses tumour growth. Results: Addition of the selective KOR agonist U50,488H to gefitinib-sensitive (HCC827) and gefitinib-resistant (H1975) NSCLC cells produced a concentration-dependent decrease in their growth. These effects were abolished by co-treatment with the selective KOR antagonist nor-BNI. Furthermore, the growth-inhibitory effect of gefitinib in HCC827 cells was further enhanced by co-treatment with U50,488H. With regard to the inhibition of tumour growth, the addition of U50, 488H to H1975 cells produced a concentration-dependent decrease in phosphorylated- glycogen synthase kinase 3Β (p-GSK3Β).Conclusion:The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3Β.

KW - κ-opioid receptor

KW - gefitinib

KW - non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84858285511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858285511&partnerID=8YFLogxK

U2 - 10.1038/bjc.2011.574

DO - 10.1038/bjc.2011.574

M3 - Article

C2 - 22343623

AN - SCOPUS:84858285511

VL - 106

SP - 1148

EP - 1152

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -